1997 TAGlines
Table of Contents
- Volume 4, Issue 11 - December 1997
- The Worldwide Epidemic: Global AIDS Picture Worsens; Global Infectious Causes of Death (Table); The Future of AIDS (Table; The Twilight of Eradication: Infectious HIV Persists After Up to 2 1/2 Years of Triple Drug Therapy
- Volume 4, Issue 10 - November 1997
- The FDA Decides the Fate of Two Drugs for AIDS-Related Malignancies; Three New Antivirals Trickle From the Pipeline; Hamburg Highlights
- Volume 4, Issue 9 - October 1997
- Republicans and Pharmaceutical Industry Target the FDA; Low Key Dual Combo Appears First to Achieve the Unimaginable
- Volume 4, Issue 8 - September 1997
- Would-Be Eradicatee Looks Forward to Still Uncertain Future; Data from the 23rd ACTG Meeting Document Reduction in Number of Opportunistic Infections in the Era of HAART; The Opportunistic Infections of ACTG 320
- Volume 4, Issue 7 - August 1997
- Roche Racks Up Millions In Early Saquinavir Sales While Unwitting Patients Prime Themselves for Protease X-Resistance; Metabolic Disturbances in HIV Infection Find Friend Not Foe in Protease Inhibitor Regimens; How the Triple Combos Stack Up
- Volume 4, Issue 6 - June/July 1997
- Panel Embraces Maximum Viral Suppression as Goal of Therapy; Drug Company Bonanza Creates Headaches for Third-Party Payers and AIDS Treatment Educators; Birth of a Paradigm
- Volume 4, Issue 5 - May 1997
- Under the Knife - HIV-Infected Kids; Immune Boost - A Report from the 4th Conference on Retroviruses
- Volume 4, Issue 4 - April 1997
- Nelfinavir Becomes Fourth Protease Inhibitor to Hit Pharmacy Shelves; Government Study Finds Protease Based Triple Combination Keeps Patients Alive Longer Than Double Nuke; Sweating the Switch Between Protease Inhibitors
- Volume 4, Issue 3 - March 1997
- The Need for 'Strategy' Type Clinical Studies; Opportunistic Infections Continue to Vex the Lives of PWAs as Long As Immunodeficiency Remains; Treating OIs: How We're Doing
- Volume 4, Issue 2 - February 1997
- Druthers, Grim: Frightening Tales of Multiply Resistant HIV from D.C. Principles Panel; Backstepped: Dutch Research Team Challenges Ho/Shaw Pathogenetic HIV
Model; Staring into the Precipice: resistance and cross-resistance among protease inhibitors
- Volume 4, Issue 1 - January 1997
- Delavirdine Disappoints at FDA, HIV in Lymphoid Tissue, and More from November's NIH AIDS Panel, Recent Research in Brief
Always watch for outdated information. These articles first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor. TAGline is published monthly by the Treatment Action Group (TAG), a 501(c)(3) non-profit treatment advocacy organization in New York City. Copyright © 1997 - Treatment Action Group (TAG), 200 East 10th Street, #60, New York, NY 10003, phone: (212) 260-0300, fax: (212) 260-8561. All rights reserved. No part of this publication may be copied or reproduced in any form or by any means without the written permission of Treatment Action Group.